ANA598 to Advance into Phase IIb.  In October, Anadys announced plans to conduct a Phase IIb study of ANA598 in combination with Pegasys® (peginterferon alfa-2a) and Copegus® (ribavirin, USP) (a current standard of care, or SOC) for the treatment of chronic hepatitis C.  In the planned study, which is on track to commence early in the first quarter of 2011, approximately 200 chronically infected hepatitis C patients are expected to receive ANA598 200 mg bid in combination with SOC, while approximately 66 are to receive placebo and SOC.  Enrollment is expected to include approximately equal numbers of treatment-naïve patients and treatment-experienced patients who have failed a prior course of SOC, including difficult to treat prior null-responders.  Treatment duration for naïve patients will be response-guided, while treatment-experienced patients are to receive all three agents for 48 weeks.  On-treatment response and safety data through 24 weeks is expected in the second half of 2011. Anadys is currently finalizing discussions with the U.S. Food and Drug Administration (FDA) regarding details of the trial design, and plans to conduct the study at a number of sites within and outside the United States.  

ANA598 Data at AASLD.  On October 31, 2010, data from the ongoing Phase IIa trial of ANA598 in combination with SOC were presented in an oral presentation at the 61st Annual Meeting of the American Association for the Study of Liver Disease (AASLD).  The presented data showed that ANA598 added to SOC
'/>"/>